Adding insulin glargine versus rosiglitazone: Health-related quality-of-life impact in type 2 diabetes

Diabetes Care

Volumn 30, Issue 4, 2007, Pages 795-800

  Vinik, Aaron I ^a   Zhang, Quanwu ^b  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN GLARGINE; METFORMIN; ROSIGLITAZONE; SULFONYLUREA;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTRESS SYNDROME; DRUG DOSE TITRATION; EYE DISEASE; FATIGUE; FEMALE; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MOOD DISORDER; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SHORT FORM 36; SINGLE DRUG DOSE;

ADULT; AGED; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; FEMALE; HEALTH STATUS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; THIAZOLIDINEDIONES;

EID: 34147122186     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc06-1712     Document Type: Article

References (19)

1. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.N Engl J Med 329:977-986, 1993
2. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
3. Turner RC, Cull CA, Frighi V, Holman RR, for the UK Prospective Diabetes Study (UKPDS) Group: Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 281:2005-2012, 1999
4. Wright A, Burden ACF, Paisey RB, Cull CA, Holman RR, for the U.K. Prospective Diabetes Study Group: Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 25:330-336, 2002
5. Hunt LM, Valenzuela MA, Pugh JA: NIDDM patients' fears and hopes about insulin therapy: the basis of patient reluctance. Diabetes Care 20:292-298, 1997
6. Korytkowski M: When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 26 (Suppl. 3):S18-S24, 2002
7. Goddijn PPM, Bilo HJG, Feskens EJM, Groeniert KH, van der Zee KI, Meyboom-de Jong B: Longitudinal study on glycaemic control and quality of life in patients with type 2 diabetes mellitus referred for intensified control. Diabet Med 16:23-30, 1999
8. Pibernik-Okanović M, Szabo S, Metelko Ž: Quality of life following a change in therapy for diabetes mellitus. Pharmacoeconomics 14:201-207, 1998
9. Fischer JS, McLaughlin T, Loza L, Beauchamp R, Schwartz S, Kipnes M: The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study. Curr Med Res Opin 20:1703-1710, 2004
10. de Sonnaville JJJ, Snoek FJ, Colly LP, Devillé W, Wijkel D, Heine RJ: Well-being and symptoms in relation to insulin therapy in type 2 diabetes. Diabetes Care 21:919-924, 1998
11. Davis TME, Clifford RM, Davis WA: Effect of insulin therapy on quality of life in type 2 diabetes mellitus: the Fremantle Diabetes Study. Diabetes Res Clin Pract 52:63-71, 2001
12. U.K. Prospective Diabetes Study Group: Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care 22:1125-1136, 1999
13. Strowig SM, Avilés-Santa ML, Raskin P: Improved glycemic control without weight gain using triple therapy in type 2 diabetes. Diabetes Care 27:1577-1583, 2004
14. LeRoith D, Fonseca V, Vinik A: Metabolic memory in diabetes-focus on insulin. Diabete Metab Res Rev 21:85-90, 2005
15. Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G, on behalf of the Insulin Glargine 4014 Study Investigators: Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naïve patients. Diabetes Care 29:554-559, 2006
16. Grootenhuis PA, Snoek FJ, Heine RJ, Bouter LM: Development of a type 2 diabetes symptom checklist: a measure of symptom severity. Diabet Med 11:253-261, 1994
17. Ware JE Jr, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30:473-483, 1992
18. Hu L-T, Bentler P: Cutoff criteria for fit indexes in covariance structure analysis: conventional criteria versus new alternatives. Structural Equation Modeling 6:1-55, 1999
19. Vinik EJ, Hayes RP, Oglesby A, Bastyr E, Barlow P, Ford-Molvik SL, Vinik AI: The development and validation of the Norfolk QOL-DN, a new measure of patients' perception of the effects of diabetes and diabetic neuropathy. Diabetes Technol Ther 7:497-508, 2005